Secondary prevention in thrombotic antiphospholipid syndrome

被引：11

作者：

Pengo, V. ^{[1
]}

Denas, G. ^{[1
]}

Banzato, A. ^{[1
]}

Bison, E. ^{[1
]}

Bracco, A. ^{[1
]}

Facchinetti, M. ^{[2
]}

Hoxha, A. ^{[2
]}

Ruffatti, A. ^{[2
]}

机构：

[1] Univ Padua, Thrombosis Ctr, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy

[2] Univ Padua, Rheumatol Unit, Dept Med, I-35128 Padua, Italy

来源：

LUPUS | 2012年 / 21卷 / 07期

关键词：

antiphospholipid; prevention; drugs; thrombosis; RECURRENT THROMBOSIS; THERAPY; INTENSITY; WARFARIN; RISK;

D O I：

10.1177/0961203312444773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0. The optimal intensity of anticoagulation was determined in two prospective randomized controlled trials, both excluding the benefit of more intense anticoagulation. The same regimen is also recommended in patients with APS and arterial thromboembolism as aspirin does not appear to protect against recurrences. The duration of treatment is usually indefinite because of a substantial risk of recurrence. Lupus (2012) 21, 734-735.

引用

页码：734 / 735

页数：2

共 50 条

[1] HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
Belizna, Cristina
Pregnolato, Francesca
Abad, Sebastien
Alijotas-Reig, Jaume
Amital, Howard
Amoura, Zahir
Andreoli, Laura
Andres, Emmanuel
Aouba, Achile
Bilgen, Sule Apras
Arnaud, Laurent
Bienvenu, Boris
Bitsadze, Viktoria
Blanco, Patrick
Blank, Miri
Borghi, Maria Orietta
Caligaro, Antonia
Candrea, Elisabeta
Canti, Valentina
Chiche, Laurent
Chretien, Jean Marie
Tervaert, Jan Willem Cohen
Damian, Laura
Delross, Teresa
Dernis, Emmanuelle
Devreese, Katrien
Djokovic, Aleksandra
Esteve-Valverde, Enrique
Favaro, Maria
Fassot, Celine
Ferrer-Oliveras, Raquel
Godon, Alban
Hamidou, Mohamed
Hasan, Milena
Henrion, Daniel
Imbert, Bernard
Jeandel, Pierre Yves
Jeannin, Pascale
Jego, Patrick
Jourde-Chiche, Noemie
Khizroeva, Jamilya
Lambotte, Olivier
Landron, Cedric
Omar Latino, Jose
Lazaro, Estibaliz
de Leeuw, Karina
Le Gallou, Thomas
Kilic, Levent
Limper, Maarten
Loufrani, Laurent
AUTOIMMUNITY REVIEWS, 2018, 17 (12) : 1153 - 1168
[2] Thrombotic antiphospholipid syndrome
Sciascia, S.
Radin, M.
LUPUS, 2018, 27 : 21 - 27
[3] What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?
Arachchillage, Deepa R. J.
Laffan, Mike
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : 216 - 227
[4] Rivaroxaban to treat thrombotic antiphospholipid syndrome
Urbanus, Rolf T.
Lancet Haematology, 2016, 3 (09): : E403 - E404
[5] Treatment in thrombotic antiphospholipid syndrome: a review
Vadgama, T. S.
Smith, A.
Bertolaccini, M. L.
LUPUS, 2019, 28 (10) : 1181 - 1188
[6] Clinical Management of Thrombotic Antiphospholipid Syndrome
Tumian, Nor Rafeah
Hunt, Beverley J.
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (03)
[7] Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Resseguier, A. S.
Pereira, B.
Rieu, V.
Le Guenno, G.
Grobost, V.
Ruivard, M.
LUPUS, 2017, 26 (12) : 1297 - 1303
[8] Towards evidence-based treatment of thrombotic antiphospholipid syndrome
Derksen, R. H. W. M.
de Groot, P. G.
LUPUS, 2010, 19 (04) : 470 - 474
[9] Platelets and Thrombotic Antiphospholipid Syndrome
Tohidi-Esfahani, Ibrahim
Mittal, Prabal
Isenberg, David
Cohen, Hannah
Efthymiou, Maria
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
[10] Treatment of thrombotic antiphospholipid syndrome in adults and children
Madison, Jacqueline A.
Duarte-Garcia, Ali
Zuo, Yu
Knight, Jason S.
CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (03) : 215 - 227

← 1 2 3 4 5 →